312 nm UVB Phototherapy Limits Atherosclerosis by Regulating Immunoinflammatory Responses in Mice.
We demonstrated that 312 nm UVB irradiation limits atherosclerosis by favorably modulating the T cell balance and lipid mediator profile. Our findings indicate that 312 nm UVB phototherapy could be an attractive immunomodulatory approach for preventing and treating atherosclerosis.
Authors
- Yoshiyuki Rikitake (ORCID: https://orcid.org/0000-0001-7207-4656)
- Atsushi Fukunaga (ORCID: https://orcid.org/0000-0003-2026-8154)
- Masakazu Shinohara (ORCID: https://orcid.org/0000-0001-8724-0071)
- Hilman Zulkifli Amin (ORCID: https://orcid.org/0000-0003-0659-9678)
- Naoto Sasaki (ORCID: https://orcid.org/0000-0002-7760-6129)
- Motoaki Iwaya (ORCID: https://orcid.org/0000-0002-4889-706X)
- Sayo Horibe (ORCID: https://orcid.org/0000-0002-4111-2426)
- Aga Krisnanda (ORCID: https://orcid.org/0009-0005-6417-2738)
- Toru Tanaka (ORCID: https://orcid.org/0000-0002-1054-9211)
- Ken Ito (ORCID: https://orcid.org/0009-0007-8678-1862)
- Ken-ichi Hirata
Institutions
- Kobe Pharmaceutical University (JP)
- University of Indonesia (ID)
- National Cerebral and Cardiovascular Center (JP)
- Kagawa Prefectural Central Hospital (JP)
- Kobe University (JP)
- Osaka University of Pharmaceutical Sciences (JP)
- Meijo University (JP)
Publication Details
- Journal
- PubMed
- Published
- 2025-02-03
- DOI
- https://doi.org/10.24546/0100492952
- Primary Topic
- Atherosclerosis and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- Suzuken Memorial Foundation
- Astellas Pharma
- Astellas Foundation for Research on Metabolic Disorders
- SENSHIN Medical Research Foundation
- Novartis Pharma
- Pfizer Japan
- Japan Society for the Promotion of Science